SCHEMBL6007430

SCHEMBL6007430

S=[C]NCc1cc2ccccc2s1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 5/20 0.64
ADRB2 P07550 1/20 0.64
ASIC3 Q9UHC3 1/20 0.55
LOXL2 Q9Y4K0 1/20 0.55
AGXT P21549 1/20 0.50
KDM4C Q9H3R0 1/20 0.43
ADRA1D P25100 2/20 0.42
FAAH O00519 1/20 0.40
HDAC1 Q13547 2/20 0.40
S1PR4 O95977 2/20 0.40
S1PR5 Q9H228 2/20 0.40
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC9 Q9UKV0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1176901 0.82 CYP2A6 (0.64) CYP2A6ADRB2ASIC3LOXL2AGXT
SCHEMBL1254283 0.78 CYP2A6 (1.00) CYP2A6ADRB2ASIC3LOXL2AGXT
SCHEMBL3106945 0.75 CYP2A6 (0.64) CYP2A6ADRB2ASIC3LOXL2AGXT
SCHEMBL4961407 0.74 CYP2A6 (0.69) CYP2A6ADRB2ASIC3LOXL2AGXT
SCHEMBL15961524 0.74 CYP2A6 (0.67) CYP2A6ADRB2ASIC3LOXL2AGXT
SCHEMBL1176902 0.74 CYP2A6 (0.62) CYP2A6ADRB2ASIC3LOXL2AGXT
SCHEMBL12890744 0.74 CYP2A6 (0.67) CYP2A6ADRB2ASIC3LOXL2AGXT
SCHEMBL13123451 0.74 CYP2A6 (0.53) CYP2A6ADRB2ASIC3LOXL2AGXT
SCHEMBL16597960 0.74 CYP2A6 (0.62) CYP2A6ADRB2ASIC3LOXL2AGXT
SCHEMBL11206756 0.72 CYP2A6 (0.61) CYP2A6ADRB2ASIC3LOXL2AGXT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1207161-B1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2006-01-18 EP disclosed
US-6777410-B2 SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-08-17 US disclosed
US-20040053923-A1 Novel isoindole derivatives BANYU PHARMACEUTICAL CO., LTD. 2004-03-18 US disclosed
US-6608098-B1 Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide BANYU PHARMACEUTICAL CO., LTD. (JP) 2003-08-19 US disclosed
EP-1207161-A1 NOVEL ISOINDOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2002-05-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053923-A1 Novel isoindole derivatives GPR119, SLC5A2, SLC5A1 CYP2A6 833/4885ADRB2 49/4885ASIC3 1168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.